SurModics, a US-based provider of medical devices and in-vitro diagnostic technologies, has completed the enrolment of the first patient in an early feasibility study of its SurVeil drug-coated balloon (DCB).

The study will enrol up to 15 patients to collect data on product safety and usability before concluding on the product design.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company has identified three clinical sites to participate in this early feasibility study for the SurVeil DCB.

"The new generation of DCBs, which includes significant advances in technology, provides a great opportunity to further enhance patient outcomes."

The DCBs are considered instrumental in treating peripheral artery disease (PAD). It aims to administer the correct dosage of antiproliferative drug at the site of a lesion, and applies the drug uniformly to the arterial wall by reducing the drug release into the blood stream during the procedure.

The SurVeil DCB is the first complete vascular medical device developed by the company featuring its patented drug-excipient formulation for the balloon coating, and a new and proprietary manufacturing process for the coating applications.

See Also:

It also includes the SurModics Serene low-friction, low-particulate hydrophilic coating on the catheter shaft.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SurModics Scientific Advisory Board chairman and Massachusetts General Hospital vascular medicine and intervention section head Kenneth Rosenfield said: "First and second generation DCBs demonstrated a biologic effect and improved patency in patients with PAD.

"The new generation of DCBs, which includes significant advances in technology, provides a great opportunity to further enhance patient outcomes."

Last year, the study was granted an investigational device exemption (IDE) approval by the FDA.